IP Library Granted Patent US 6,946,556
Granted Patent B1
US 6,946,556 · App. 10/851,528 · Granted Sep 20, 2005

Preparation of opioid analgesics by a one-pot process

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,946,556
App. No.
10/851,528
Granted
Sep 20, 2005
Kind
B1
Abstract

A one-pot process for preparing opioid analgesics such as hydrocodone, hydromorphone, and analogues thereof by reacting codeine, morphine, and analogues thereof with hydrogen in a solvent system of benzophenone and neutral solvent in the presence of a metal catalyst followed by oxidation in the presence of potassium tert-alkylate.

Claims (32)

1. A process for the preparation a compound of formula (I)

wherein R′ is hydrogen, methyl or alcohol protecting group; R″ is hydrogen, methyl or amine protecting group, comprising the steps of:

(i) reacting a compound of formula (II)

with hydrogen in a solvent system of benzophenone and neutral solvent in the presence of metal catalyst, to generate a reaction mixture containing compound of formula (III);

and

(ii) reacting reaction mixture containing compound of formula (III) with potassium tert-alkylate to yield a compound of formula (I).

2. The process of claim 1 , wherein the neutral solvent is selected from the group consisting of cyclohexane, toluene, heptane, diisopropyl ether, tetrahydrofuran, 1,4-dioxane, methyl-tert-butyl ether, tert-butyl alcohol, tert-amyl alcohol and combinations thereof.

3. The process of claim 1 , wherein the metal catalyst is selected from the group consisting of nickel, palladium, rhodium, ruthenium, platinum, and combinations thereof.

4. The process of claim 1 , wherein potassium tert-alkylate is selected from the group consisting of potassium tert-amylate and potassium tert-butylate, and combinations thereof.

5. The process of claim 1 , wherein the molar ratio of compound of formula (II) to benzophenone is in the range of about 1:3 to about 1:20.

6. The process of claim 5 , wherein the molar ratio of compound of formula (II) to benzophenone is in the range of about 1:5 to about 1:12.

7. The process of claim 6 , wherein the molar ratio of compound of formula (II) to benzophenone is in the range of about 1:6 to about 1:9.

8. The process of claim 1 , wherein the concentration of benzophenone in the said solvent system is in the range from about 5% to about 99%.

9. The process of claim 8 , wherein the concentration of benzophenone in the said solvent system is in the range from about 10% to about 75%.

10. The process of claim 9 , wherein the concentration of benzophenone in the said solvent system is in the range from about 25% to about 50%.

11. The process of claim 3 , wherein metal catalyst is suitable for heterogeneous hydrogenation.

12. The process of claim 11 , wherein the metal catalyst is supported on the support selected from the group consisting of carbon, barium sulfate, silicon oxide, calcium carbonate, alumina, and combinations thereof.

13. The process of claim 3 , wherein the metal catalyst is suitable for homogeneous hydrogenation.

14. The process of claim 13 , wherein the metal catalyst is chlorotris(triphenylphosphine)rhodium.

15. The process of claim 3 , wherein the metal catalyst is present in the amounts from about 0.01 to about 10 mol % of the compound of formula (II).

16. The process of claim 15 , wherein the metal catalyst is present in the amounts from about 0.05 to about 5 mol % of the compound of formula (II).

17. The process of claim 16 , wherein the metal catalyst is present in the amounts from about 0.25 to about 3 mol % of the compound of formula (II).

18. The process of claim 1 , wherein step (i) is performed at temperature range from about 5° C. to about 110° C.

19. The process of claim 18 , which is performed at temperature range from about 15° C. to about 60° C.

20. The process of claim 19 , which is performed at temperature range from about 20° C. to about 45° C.

21. The process of claim 1 , wherein potassium tert-alkylate is present in amounts between about 1 to about 5 equivalents relative to the amount of compound of formula (II).

22. The process of claim 21 , wherein potassium tert-alkylate is present in amounts between about 1.4 to about 4 equivalents relative to the amount of compound of formula (II).

23. The process of claim 1 , wherein temperature in step (ii) is from about 15° C. to about 110° C.

24. The process of claim 23 , wherein temperature is from about 20° C. to about 80° C.

25. The process of claim 24 , wherein temperature is from about 25° C. to about 60° C.

26. The process of claim 1 , wherein the compound of formula (I) is selected from the group consisting of hydrocodone, and hydromorphone.

27. The process of claim 1 , wherein the metal catalyst is selected from group VIII of the Periodic Table of Elements.

Assignments (11)
SECURITY INTEREST Recorded Jul 2, 2019
From: ACURA PHARMACEUTICALS, INC.
To: SCHUTTE, JOHN
Reel/Frame 049649/0950 →
SECURITY INTEREST Recorded Jul 2, 2019
From: SCHUTTE, JOHN
To: ABUSE DETERRENT PHARMACEUTICALS, LLC
Reel/Frame 049650/0104 →
RELEASE OF SECURITY INTEREST Recorded Oct 11, 2018
From: OXFORD FINANCE LLC
To: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICALS TECHNOLOGIES, INC.
Reel/Frame 047140/0800 →
SECURITY INTEREST Recorded Mar 17, 2017
From: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICAL TECHNOLOGIES, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 041623/0740 →
CHANGE OF NAME Recorded Jun 8, 2011
From: HALSEY DRUG CO, INC.
To: ACURA PHARMACEUTICALS, INC.
Reel/Frame 026408/0220 →
RELEASE OF SECURITY INTEREST Recorded Oct 10, 2007
From: GALEN PARTNERS III, L.P.
To: ACURA PHARMACEUTICALS, INC.
Reel/Frame 019930/0568 →
SECURITY AGREEMENT Recorded Jan 31, 2006
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 017097/0150 →
SECURITY AGREEMENT Recorded Nov 11, 2005
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 016769/0109 →
SECURITY INTEREST Recorded Sep 19, 2005
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 016814/0160 →
SECURITY INTEREST Recorded Jun 22, 2005
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 016408/0558 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2004
From: LIKHOTVORIK, IGOR; LISOWSKI, JOSEPH J.
To: HALSEY DRUG COMPANY, INC.
Reel/Frame 014796/0046 →